Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We review the cardiovascular and renal outcomes and safety of newer anti-diabetic medications in high-risk patients. We examine the outcomes of the IRIS, EMPA-REG OUTCOME, CANVAS, LEADER, SAVOR-TIMI 53, and EXAMINE trials demonstrating the cardiovascular and renal benefits of thiazolidinediones, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors.

Recent Findings

Diabetes mellitus is a leading risk factor for cardiovascular disease with rising prevalence and disease burden. The microvascular and macrovascular complications of diabetes are well-recognized and include increased risk of cardiovascular disease, myocardial infarction, and stroke. Newer diabetes medications have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality benefits in high risk patients with diabetes. In addition to their glucose-lowering effects, the thiazolidinedione pioglitazone, SGLT2 inhibitors, GLP-1 agonist, and DPP-4 inhibitors have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality effects.

Summary

The outcomes and safety data of newer diabetes medications from recent trials demonstrate cardiovascular and mortality effects with significant implications for clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Di Angelantoni E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;324:52–60.

    Google Scholar 

  2. Golden S. Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. Am J Card. 2011;108:59B–67B.

    Article  PubMed  CAS  Google Scholar 

  3. National Diabetes Statistics Report. Centers for disease control. 2017

  4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM. 2008;358:2545–59.

    Article  Google Scholar 

  5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  6. Holman R, Paul S, Bethel M, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM. 2008;359:1577–89.

    Article  PubMed  CAS  Google Scholar 

  7. •• Kernan W, Viscoli C, Furie K, et al. Pioglitazone after ischemic stroke or transient ischemic attack. NEJM. 2016;374:1321–31. This is a publication of the IRIS trial methods, findings and conclusions.

    Article  PubMed  CAS  Google Scholar 

  8. •• Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015;373:2117–28. This is a publication of the EMPA-REG trial methods, findings and conclusions.

    Article  PubMed  CAS  Google Scholar 

  9. •• Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM. 2017;377:644–57. This is a publication of the EMPA-REG trial methods, findings and conclusions.

    Article  PubMed  CAS  Google Scholar 

  10. •• Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. NEJM. 2016;374:311–22. This is a publication of the cardiovascular outcomes of the LEADER Trials.

    Article  CAS  Google Scholar 

  11. Scirica B, Bhatt D, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEJM. 2013;369:1317–26.

    Article  PubMed  CAS  Google Scholar 

  12. White W, Cannon C, Heller S, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEJM. 2013;369:1327–35.

    Article  PubMed  CAS  Google Scholar 

  13. Chiarelli F, Di Marzio D. Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008;4:297–304.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Mearns E, Saulsberry W, White C, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med. 2015;32:1530–40.

    Article  PubMed  CAS  Google Scholar 

  15. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5:355–66.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Cefalu W, Riddle M. SGLT2 inhibitors: the latest “new kids on the block”! Diabetes Care. 2015;38:352–4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Saad M, Mahmoud A, Elgendy I, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017;228:352–8.

    Article  PubMed  Google Scholar 

  18. Syed S, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, et al. A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13(2):105–12.

    Article  PubMed  CAS  Google Scholar 

  19. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Kalra S, Baruah M, Sahay R, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J Endocrinol Metab. 2016;20:254–67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Knudsen L, Madsen L, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–86.

    Article  CAS  Google Scholar 

  22. •• Mann J, Orsted D, Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. NEJM. 2017;377:839–48. This is a publication of the renal outcomes from the LEADER Trials.

    Article  PubMed  CAS  Google Scholar 

  23. Ussher J, Drucker D. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–803.

    Article  PubMed  CAS  Google Scholar 

  24. Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85:579–89.

    Article  PubMed  CAS  Google Scholar 

  25. Thornberry N, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23:479–86.

    Article  PubMed  CAS  Google Scholar 

  26. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34:S276–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Said S, Nwosu A, Mukherjee D, Hernandez G. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. Cardiovasc Hematol Disord Drug Targets. 2014;14(1):64–70.

    Article  PubMed  CAS  Google Scholar 

  28. Graham D, Ouellet-Hellstrom R, MaCurdy T, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.

    Article  PubMed  CAS  Google Scholar 

  29. • Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. NEJM. 2015;373:2247–57. This study details the noninferiority of GLP-1 agonist, lixisenatide to placebo in cardiovascular outcomes.

    Article  PubMed  CAS  Google Scholar 

  30. Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care. 2016;39:S210–8.

    Article  PubMed  CAS  Google Scholar 

  31. • Green J, Bethel M, Armstrong P, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. NEJM. 2015;373:232–42. This study details the noninferiority of DPP-4 inhibitor, sitagliptin to placebo in cardiovascular outcomes.

    Article  PubMed  CAS  Google Scholar 

  32. Filion K, Azoulay L, Platt R, Dahl M, Dormuth CR, Clemens KK, et al. A multicenter observational study of incretin-based drugs and heart failure. NEJM. 2016;374:1145–54.

    Article  PubMed  CAS  Google Scholar 

  33. Fu A, Johnston S, Ghannam A, et al. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39:726–34.

    Article  PubMed  CAS  Google Scholar 

  34. Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ. 2016;352:i610.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol. 2016;211:88–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic, Department of Endocrinology, Diabetes and Metabolism, 9500 Euclid Ave. F20, Cleveland, OH, 44195, USA

    Lima Lawrence & Sangeeta Kashyap

  2. Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Ave. J1-5, Cleveland, OH, 44195, USA

    Venu Menon

Authors
  1. Lima Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Venu Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sangeeta Kashyap
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sangeeta Kashyap.

Ethics declarations

Conflict of Interest

Lima Lawrence and Venu Menon declare that they have no conflict of interest.

Sangeeta Kashyap reports grants from Janssen.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lawrence, L., Menon, V. & Kashyap, S. Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. Curr Cardiol Rep 20, 65 (2018). https://doi.org/10.1007/s11886-018-1005-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-018-1005-8

Keywords

Search

Navigation